Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2011, Article ID 125467, 5 pages
http://dx.doi.org/10.1155/2011/125467
Case Report

The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series

1Division of Hematology and Oncology, Department of Medicine, Columbia University, New York, NY 10032-3784, USA
2Griffin Hospital, Yale University School of Medicine, 130 Division Street, Derby, New Haven, CT 06418, USA
3Division of Medical Oncology, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
4Third Department of Medicine, Athens University School of Medicine, Building Z, Sotiria General Hospital, Mesogion 152 115 27 Athens, Greece

Received 17 January 2011; Revised 14 April 2011; Accepted 15 April 2011

Academic Editor: Bruno Vincenzi

Copyright © 2011 Muhammad W. Saif et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [18 citations]

The following is the list of published articles that have cited the current article.

  • N. Schulte, and R. -D. Hofheinz, “Anal cancer,” Onkologe, vol. 18, no. 8, pp. 699–704, 2012. View at Publisher · View at Google Scholar
  • A Paliga, R Onerheim, A Gologan, G Chong, A Spatz, T Niazi, A Garant, D Macheto, T Alcindor, and T Vuong, “EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?,” British Journal of Cancer, vol. 107, no. 11, pp. 1864–1868, 2012. View at Publisher · View at Google Scholar
  • Wulfran Cacheux, Astrid Lievre, Anne De La Rochefordiere, Barbara Dieumegard, Frédérique Cvitkovic, Alain Labib, Emmanuel Mitry, and Bruno Buecher, “Chemotherapy in the treatment of anal canal carcinoma,” Digestive and Liver Disease, vol. 44, no. 10, pp. 803–811, 2012. View at Publisher · View at Google Scholar
  • Alice Dewdney, and Sheela Rao, “Metastatic Squamous Cell Carcinoma of the Anus: Time for a Shift in the Treatment Paradigm?,” ISRN Oncology, vol. 2012, pp. 1–6, 2012. View at Publisher · View at Google Scholar
  • Ingeborg Fraunholz, Franz Rödel, Daniela Kohler, Margarita Diallo-Georgiopoulou, Luitpold Distel, Stefan Falk, and Claus Rödel, “Epidermal Growth Factor Receptor Expression As Prognostic Marker in Patients With Anal Carcinoma Treated With Concurrent Chemoradiation Therapy,” International Journal of Radiation Oncology*Biology*Physics, 2013. View at Publisher · View at Google Scholar
  • Schulte, and Hofheinz, “Anal cancer: Therapy options for localized and disseminated recurrence,” Coloproctology, vol. 35, no. 5, pp. 309–314, 2013. View at Publisher · View at Google Scholar
  • Jane E. Rogers, and Cathy Eng, “Cetuximab in Refractory Squamous Cell Carcinoma of the Anal Canal,” Journal of Gastrointestinal Cancer, 2014. View at Publisher · View at Google Scholar
  • I. Fraunholz, G. Woeste, and R.-D. Hofheinz, “Therapie des Analkarzinoms,” Der Onkologe, 2014. View at Publisher · View at Google Scholar
  • Liliana Bustamante, Jessica Frakes, Sarah Hoffe, and Richard Kim, “Investigational drugs for treating anal cancer and future perspectives,” Expert Opinion on Investigational Drugs, pp. 1–12, 2015. View at Publisher · View at Google Scholar
  • Brandon G. Smaglo, Anteneh Tesfaye, Thorvardur R. Halfdanarson, Joshua E. Meyer, Jue Wang, Zoran Gatalica, Sandeep Reddy, David Arguello, and Patrick M. Boland, “Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas,” Oncotarget, vol. 6, no. 41, pp. 43594–43604, 2015. View at Publisher · View at Google Scholar
  • Ninoska N. Silva, Cathy Eng, and Jane E. Rogers, “Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal,” Journal of Gastrointestinal Oncology, vol. 6, no. 5, pp. E82–E85, 2015. View at Publisher · View at Google Scholar
  • Bartoš, Richter, Dvořák, and Jirásek, “The possibility of epidermal growth factor receptor inhibition in anal cancer,” Klinicka Onkologie, vol. 28, no. 4, pp. 260–264, 2015. View at Publisher · View at Google Scholar
  • Mahender Yellu, Ayham Deeb, and Olugbenga Olowokure, “Overview of recent trends in the management of metastatic anal cancer,” CJAM Canadian Journal of Addiction Medicine, vol. 6, no. 1, pp. 311–315, 2015. View at Publisher · View at Google Scholar
  • Andrew Haydon, Rebecca Tay, Gabriel Mak, and Jeremy Shapiro, “Long Survival (Cure) to Cisplatin/Infusional 5-Flurouracil in Metastatic Squamous Cell Anal Cancer with Extensive Liver and Lung Metastases,” Case Reports in Clinical Medicine, vol. 04, no. 03, pp. 73–76, 2015. View at Publisher · View at Google Scholar
  • Jane E. Rogers, Aki Ohinata, Ninoska N. Silva, Amir Mehdizadeh, and Cathy Eng, “Epidermal growth factor receptor inhibition in metastatic anal cancer,” Anti-Cancer Drugs, vol. 27, no. 8, pp. 804–808, 2016. View at Publisher · View at Google Scholar
  • I. Richter, T. Jirasek, J. Dvorak, Eva Cermakova, and Jiri Bartos, “The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma,” Neoplasma, vol. 63, no. 3, pp. 435–441, 2016. View at Publisher · View at Google Scholar
  • Amit Mahipal, Yound Doo Chang, Dae Won Kim, Jennifer Byer, Nishi Kothari, and Richard D. Kim, “EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience,” Oncology (Switzerland), vol. 92, no. 4, pp. 190–196, 2017. View at Publisher · View at Google Scholar
  • Rob Glynne-Jones, and Mark Harrison, “Cetuximab in the Context of Current Treatment of Squamous Cell Carcinoma of the Anus,” Journal of Clinical Oncology, vol. 35, no. 7, pp. 699–701, 2017. View at Publisher · View at Google Scholar